Exatecan in pretreated adult patients with advanced soft tissue sarcoma: Results of a phase II - Study of the EORTC Soft Tissue and Bone Sarcoma Group

European Journal of Cancer

Volumn 43, Issue 6, 2007, Pages 1017-1022

  Reichardt, P ^a   Nielsen, O S ^b   Bauer, S ^c   Hartmann, J T ^d   Schoffski P ^e   Christensen, T B ^b   Pink, D ^a   Daugaard, S ^f   Marreaud, S ^g   Van Glabbeke, M ^g   Blay, J Y ^h  

^a Section of Pathology   (Germany)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f University of Copenhagen   (Denmark)

^g EORTC DATA CENTER   (Belgium)

^h CENTRE LÉON BÉRARD   (France)

Author keywords

Exatecan; Soft tissue sarcoma; Topoisomerase I inhibitors

Indexed keywords

EXATECAN;

ADULT; AGE DISTRIBUTION; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DYSPNEA; FATIGUE; FEMALE; HISTOLOGY; HUMAN; LEIOMYOSARCOMA; MALE; MULTICENTER STUDY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPTIC SHOCK; SOFT TISSUE SARCOMA; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; LEIOMYOSARCOMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SARCOMA, SYNOVIAL; TREATMENT OUTCOME;

EID: 33947699972     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2007.01.014     Document Type: Article

References (14)

1. Storm H.H. Survival of adult patients with cancer of soft tissues or bone in Europe. Eur J Cancer 34 (1998) 2212-2217
2. Clark M.A., Fisher C., Judson I., and Thomas J.M. Soft-tissue sarcomas in adults. N Engl J Med 353 (2005) 701-711
3. Blay J.Y., Van Glabbeke M., Verweij J., et al. Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy. Eur J Cancer 39 (2003) 64-69
4. Bramwell V.H., Eisenhauer E.A., Blackstein M., et al. Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma. Ann Oncol 6 (1995) 847-849
5. Adjei A.A., Klein C.E., Kastrissios H., et al. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. J Clin Oncol 18 (2000) 1116-1123
6. Miller D.S., Blessing J.A., Kilgore L.C., Mannel R., and Van Le L. Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas: a Gynecologic Oncology Group Study. Am J Clin Oncol 23 (2000) 355-357
7. De Jager R., Cheverton P., Tamanoi K., et al. DX-8951f: summary of phase I clinical trials. Ann N Y Acad Sci 922 (2000) 260-273
8. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
9. Budd G.T., Rankin C., Hutchins L.F., Wong L., Petruska P.J., and Antman K. Phase II trial of topotecan by continuous infusion in patients with advanced soft tissue sarcomas, a SWOG study. Invest New Drugs 20 (2002) 129-132
10. Reichardt P., Oechsle K., Pink D., et al. An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. Invest New Drugs 21 (2003) 481-486
11. Saylors III R.L., Stine K.C., Sullivan J., et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group Phase II study. J Clin Oncol 19 (2001) 3463-3469
12. Bisogno G., Riccardi R., Ruggiero A., et al. Phase II study of a protracted irinotecan schedule in children with refractory or recurrent soft tissue sarcoma. Cancer 106 (2006) 703-707
13. Patel S.R., Beach J., Papadopoulos N., et al. Results of a 2-arm phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas. Cancer 97 (2003) 2848-2852
14. Van Glabbeke M., Verweij J., Judson I., Nielsen O.S., and and on behalf of the EORTC Soft Tissue and Bone Sarcoma Group. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 38 (2002) 543-549